To validate the specificity of fluorocoxib D uptake by human 5637 cancer cells, cells were pretreated with or without 10  μM celecoxib, a COX-2 selective inhibitor for 30 min, followed by 50-nM fluorocoxib D treatment for additional 30 min. This evidence concerns the gene PTGS2 and cancer.